Date: 2014-11-06
Type of information: Opening of new premises
Compound: new Australian office in Melbourne
Company: Eisai (Japan)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On November 6, 2014, Eisai announced the official opening of a new office in Melbourne, Australia, which will further expand the company\'s geographical presence and increase patient reach. The Melbourne office will provide leading global research and development-based pharmaceutical company, Eisai, with an important platform from which its portfolio of novel oncology and epilepsy products will be marketed.
- The first two products to be supported by the new office will be novel breast cancer treatment Halaven® (eribulin) and first-in-class epilepsy treatment Fycompa® (perampanel).
- Eribulin received reimbursement in Australia on 1 October 2014. The agent is one of the few breast cancer treatments to be approved by the Australian Pharmaceutical Benefits Scheme (PBS) in recent years. It is indicated in Australia for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
- Perampanel, received reimbursement from the PBS on 1 November 2014. It is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.
Financial terms:
Latest news:
Is general: Yes
